Pharmaceutics International, Inc. (Pii), a Contract Development Manufacturing Organization (CDMO), received FDA market approval for seven new products and commercially launched six products in 2017.   In early 2017, Pii conducted a cGMP baseline risk assessment and implemented remediation initiatives to enhance its cGMP systems.  These initiatives yielded great results including successful MHRA and FDA inspections early in that year, and the approval and launch of numerous products, one ...